Biotech startups raised $2.6 billion globally in the second quarter of this year, but that’s down nearly 46% compared to the same period last year, according to a report from Pitchbook. Capital is harder to find, and the report projects an uptick in M&A activity as companies run out of cash.
The initial public offering window continues to draw a steady stream of investment from venture and private equity investors allocating funding to what’s referred to as the crossover round that precedes an IPO. That was one of the takeaways of the MoneyTree report analyzing third quarter investment trends by the National Venture Capital Association and […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
On the surface, the first quarter venture capital funding report by National Venture Capital Association and PriceWaterhouseCoopers looks like another downward trend for venture capital deal flow in the life science sector. But if you dig a little deeper there are some positive trends, too. Biotechnology companies attracted $1.1 billion across 112 deals, putting the […]
2014 will be a better year for venture capital than 2013, but that won’t necessarily mean it will be easier for entrepreneurs to raise money. And the life science IPO boom likely won’t be sustained. That’s the sentiment captured by the National Venture Capital Association and Dow Jones’ DJX VentureSource’s annual Venture View survey, which […]
Venture capital investment in the life sciences has fallen 39 percent over the past three years as the costly, lengthy process of getting approval for pharmaceuticals from the Food and Drug Administration has spurred companies to shift their investments to overseas markets in Europe and Asia. According to the survey of 150 venture capital firms, […]
Life sciences venture capital investment in the second quarter jumped 37 percent over the prior quarter on increased exit activity, according to a new report. Life sciences companies raised $2.1 million in the quarter in 206 deals. Deal volume increased 12 percent compared to the first quarter, according to the MoneyTree report. The report was […]
Among today's current medical news: MoneyTree's bad news for life sciences and good news for everyone else; doctor bashing on Twitter; healthcare M & A report; home healthcare is hurting hospitals; Lilly's Alzheimer's imaging drug gets FDA approval.
Considering the amount of venture money Minnesota and Wisconsin raised through September, you would assume the states are pretty evenly matched. But numbers are tricky things. First of all, the lion's share of Wisconsin money came from just two deals. And Minnesota is just beginning to track angel investments -- a big deal in Wisconsin.
The nation's leading venture capital trade association is forming a subgroup to advocate for policies and regulations that it says would bolster medical innovation in the United States.
Highlights of the important and the interesting from the world of healthcare: May ends with flurry of new venture dollars: Medtronic (NYSE: MDT) made the biggest investment during the month, putting $70 million in Israeli medical device company BioControl Medical. Also receiving fresh cash: Boston-based Tesaro secured $60 million in start-up funding; NOXXON Pharma of […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
As if venture capital firms didn’t have enough to worry about, Uncle Sam lowers another hammer: The House of Representatives Friday passed a bill that would significantly raise taxes on interest VC firms collect on profits from startups that go public or get bought. Tucked into a bill that extends unemployment benefits is a provision […]
If patience is a virtue, then Minnesota venture capitalists have become downright saintly. Faced with a weak economy that has stifled initial public offerings and mergers and acquisitions, local investors are still looking for exits well after the funds have closed. Throw in tougher regulatory scrutiny for medical devices and drugs and an exit can […]
I’ve been covering Minnesota venture capital for the past three years. Which means I’ve run out of words to describe how bad the state’s venture capital climate has become. So I’ll just let the numbers speak for themselves. Four Minnesota companies received only $20.1 million in venture capital during the first three months of the […]
Highlights of the important and the interesting from the world of healthcare: Ugly first quarter for VCs: The venture capital industry continues to undergo convulsive change, as first-quarter fundraising hit its lowest point since 1993, according to the National Venture Capital Association. Fundraising fell 31 percent to $3.6 billion when compared to last year’s first […]
Midwest health care start-ups attracted $780 million in investments in 2009, according to the BioEnterprise Midwest Health Care Venture Investment Report. While the number of companies winning investments last year -- 156 -- was about the same as in 2008, the dollar volume of the investments dropped 26 percent.
